Lungs of Lebanon: Supporting Cystic Fibrosis Care

1. Introduction

Cystic Fibrosis (CF) is a life-limiting genetic disorder caused by mutations in the CFTR gene, leading to chronic respiratory and digestive complications. The advent of Trikafta, a transformative combination therapy comprising elexacaftor, tezacaftor, and ivacaftor, has revolutionized CF management by addressing the root genetic cause for patients with at least one F508del mutation. Clinical data supports its significant benefits in improving lung function, reducing exacerbations, and enhancing overall quality of life for patients.

The American University Hospital of Beirut (AUHB) has taken a groundbreaking step in CF treatment by securing access to Trikafta for all eligible patients.

2. Project Overview

Starting in January 2025, the American University Hospital of Beirut will provide Trikafta at no cost to eligible Cystic Fibrosis patients. This initiative ensures that all patients under AUHB’s care will have equitable access to this life-changing therapy. Trikafta is recognized globally as a highly effective treatment that can cost up to $375,000 annually per patient in regions without subsidies or programs.

3. Financial and Social Impact

The elimination of Trikafta’s prohibitive costs alleviates a significant financial burden for patients and their families. With this medication provided free of charge, AUHB is not only ensuring access to treatment but also reshaping the financial landscape of CF care. Fundraising efforts previously focused on securing this medication can now be redirected toward other supportive initiatives, such as education, awareness campaigns, or advancing CF research.

This achievement reinforces AUHB’s commitment to providing cutting-edge medical care and underscores the importance of universal healthcare access to innovative therapies.

4. Clinical Impact

Trikafta has shown remarkable clinical outcomes in CF care:

• Improved Lung Function: Studies have demonstrated an average increase of 14% in FEV1 (Forced Expiratory Volume in 1 second), a key measure of lung function.
• Reduced Exacerbations: Patients experience a significant decrease in pulmonary complications and hospitalizations.
• Enhanced Quality of Life: With better lung health and fewer complications, patients are able to engage in daily activities, education, and work with minimal limitations.

For patients at AUHB, Trikafta represents the potential to live a near-normal lifespan with reduced health challenges, marking a new era in CF care in Lebanon and the region.

5. Conclusion

The American University Hospital of Beirut’s provision of Trikafta signifies a milestone in the treatment of Cystic Fibrosis. This initiative will improve patients’ health outcomes and alleviate the emotional and financial burdens historically associated with CF care. Consequently, there is no longer a need for fundraising campaigns to secure access to Trikafta, allowing the community to focus on supporting CF patients in other meaningful ways.

6. Recommendations

1. Patient Monitoring and Education:

   • Implement structured follow-up programs to ensure adherence and monitor Trikafta’s efficacy and safety.
   • Conduct educational workshops for patients and caregivers to optimize therapy management.

2. Research and Collaboration:

   • Support research efforts to expand treatment options and explore additional applications of CFTR modulator therapies.
   • Establish collaborations with global CF research networks to keep AUHB at the forefront of innovation in CF care.

3. Resource Reallocation:

   • Redirect fundraising efforts to support comprehensive care programs, such as nutritional support, physiotherapy, and mental health services.

7. Acknowledgments

This achievement was made possible by the dedication of the American University Hospital of Beirut’s healthcare professionals, administrative staff, and community supporters. Their collective efforts have enabled CF patients to access this revolutionary treatment, improving lives and setting a benchmark for regional healthcare excellence.